PUBLISHER: The Business Research Company | PRODUCT CODE: 1951696
PUBLISHER: The Business Research Company | PRODUCT CODE: 1951696
Dermatitis refers to conditions treated with inhibitors that reduce skin inflammation, which is marked by itchy rashes on swollen, reddish skin on the outer layer of the body. It is a broad term used to describe common skin irritation.
The main types of drugs used in dermatitis include corticosteroids, emollients or moisturizers, antihistamines, calcineurin inhibitors, antibiotics, immunomodulators, and interleukin inhibitors. Corticosteroids are a class of steroid hormones produced by the adrenal cortex in vertebrates, and synthetic versions of these hormones also exist. They can be administered via topical, oral, or injectable routes and are utilized in the treatment of cancer, blood disorders, chronic illnesses, and infectious diseases. These drugs are made available through a variety of channels, including hospitals, retail pharmacies, drug stores, and online or mail-order pharmacies.
Tariffs have increased the cost of imported dermatology drugs and biologics used in the treatment of skin disorders. These impacts are most evident in markets that rely on cross border sourcing for specialty dermatology therapies. Rising tariff related expenses have placed pressure on pricing structures and reimbursement dynamics for branded and generic dermatology products. This has influenced procurement decisions and product availability across hospital and retail channels. However, tariffs are also supporting domestic pharmaceutical manufacturing, local formulation capacity, and stronger regional supply chains over the long term.
The dermatitis market research report is one of a series of new reports from The Business Research Company that provides dermatitis market statistics, including dermatitis industry global market size, regional shares, competitors with a dermatitis market share, detailed dermatitis market segments, market trends and opportunities, and any further data you may need to thrive in the dermatitis industry. This dermatitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The dermatitis market size has grown steadily in recent years. It will grow from $7.06 billion in 2025 to $7.36 billion in 2026 at a compound annual growth rate (CAGR) of 4.3%. The growth in the historic period can be attributed to high prevalence of skin disorders, availability of corticosteroids, dermatologist visits growth, environmental triggers, use of antihistamines.
The dermatitis market size is expected to see steady growth in the next few years. It will grow to $8.94 billion in 2030 at a compound annual growth rate (CAGR) of 5.0%. The growth in the forecast period can be attributed to innovation in biologics, rising pollution-related skin issues, growth in dermatology clinics, increased self-care awareness, aging population. Major trends in the forecast period include growing use of biologic therapies, rising demand for topical treatments, expansion of immunomodulatory drugs, increased awareness of chronic skin conditions, growth of otc dermatology products.
The rising incidence of dermatitis is expected to drive the growth of the dermatitis market in the coming years. Dermatitis encompasses a group of inflammatory skin disorders marked by redness, itching, and irritation, often triggered by allergens, environmental factors, immune responses, or genetic susceptibility. The increase in dermatitis cases is largely attributed to greater exposure to environmental allergens and irritants in contemporary lifestyles, which provoke immune system overreactions, leading to skin inflammation and barrier disruption. This rise in dermatitis cases fuels the market by boosting demand for effective treatment options, such as topical steroids, calcineurin inhibitors, antihistamines, moisturizers, and advanced biologic therapies designed to reduce inflammation and enhance patient outcomes. For example, in March 2025, the American Pharmacists Association, a US-based professional organization for pharmacists, reported that approximately 33 million Americans were living with at least one food allergy, impacting around 8 percent of children and 11 percent of adults. Consequently, the growing prevalence of dermatitis is supporting the expansion of the dermatitis market.
Major companies operating in the dermatitis market are developing clean-label, steroid-free products such as ARCTIVA to gain a competitive edge and expand their product portfolios. ARCTIVA is a collection of steroid-free skincare products formulated to manage skin conditions like eczema and psoriasis, incorporating the innovative Hydrosurf Glycolipid Technology. For example, in April 2023, Arctiva Wellness, LLC, a US-based company focused on clean-label skincare, launched ARCTIVA, an advanced range of non-prescription, steroid-free skincare solutions designed to effectively treat skin conditions such as eczema and psoriasis. This transformative skincare line combines cutting-edge scientific research with natural, cruelty-free ingredients, along with clinically validated, FDA-approved active components to ensure proven results. Importantly, it is the only product line on the market to feature the revolutionary Hydrosurf Glycolipid Technology, a distinctive blend of fermented ingredients with notable skincare benefits, originally discovered in Antarctica.
In June 2024, Johnson & Johnson, a US-based healthcare company, acquired Proteologix, Inc., for an undisclosed sum. Through this acquisition, Johnson & Johnson intends to enhance its dermatitis treatment portfolio by incorporating Proteologix's innovative dermatologic therapies and proprietary formulations, facilitating the development of advanced solutions for inflammatory skin conditions. Proteologix, Inc. is a US-based biotechnology company focused on dermatology, with a strong track record in the research and development of therapies for dermatitis and related skin disorders.
Major companies operating in the dermatitis market are LEO Pharma AS, Regeneron Pharmaceuticals Inc., Sanofi S.A., Encore Dermatology Inc., Meda Pharmaceuticals Inc., Allergan Plc, Anacor Pharmaceutical Inc., Astellas Pharma Inc., Mylan N.V., Valeant Pharmaceutical Inc., Galderma SA, Connetics Corporation, Fujisawa Pharmaceutical Company Ltd., AbbVie Inc., Valeant Pharmaceuticals International Inc., GlaxoSmithKline plc, Medimmune Inc., Bausch Health Co. Inc., Nestle Skin Health India Pvt. Ltd., Aqua Pharmaceuticals Pvt. Ltd., Biofrontera AG, Zydus Lifesciences Limited
North America was the largest region in the dermatitis market in 2025. Middle East is expected to be the fastest-growing region in the dermatitis market report during the forecast period. The regions covered in the dermatitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the dermatitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The dermatitis market consists of sales of Stasis dermatitis, atopic dermatitis, and irritant contact dermatitis. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Dermatitis Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses dermatitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for dermatitis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The dermatitis market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.